Genmab A/S (OTCMKTS:GNMSF) Sees Large Increase in Short Interest

Genmab A/S (OTCMKTS:GNMSF) saw a significant growth in short interest in December. As of December 15th, there was short interest totalling 119,300 shares, a growth of 9.4% from the November 30th total of 109,000 shares. Based on an average daily volume of 4,500 shares, the days-to-cover ratio is currently 26.5 days.

Genmab A/S Stock Down 0.8 %

Shares of OTCMKTS:GNMSF opened at $207.38 on Thursday. The stock has a market cap of $13.56 billion, a price-to-earnings ratio of 19.94 and a beta of 1.03. The business’s 50 day moving average is $214.23 and its 200 day moving average is $241.92. Genmab A/S has a 12-month low of $192.20 and a 12-month high of $334.33.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.